Antipsychotics in the Emergency Department: High-Yield MRCEM Primary Pharmacology Revision Notes and Practice Questions

Antipsychotic drugs present the Emergency Department clinician with a dual challenge: managing patients whose prescribed antipsychotics contribute to acute medical complications, and assessing those who arrive following deliberate or accidental overdose. For candidates undertaking MRCEM Primary pharmacology revision, antipsychotics are a high-yield topic precisely because the exam tests mechanistic understanding rather than rote lists. A candidate who understands why haloperidol causes extrapyramidal side effects but quetiapine rarely does, or why clozapine demands haematological monitoring, will answer correctly across a range of question stems. This article consolidates the core receptor pharmacology, adverse-effect mechanisms, toxicological presentations, and ED management relevant to the MRCEM Primary and MRCEM SBA examinations.

Clinical Context: Why Antipsychotics Matter in the ED

Antipsychotic drugs are among the most commonly encountered prescribed medications in patients attending UK emergency departments. Schizophrenia affects approximately 1 in 100 people over a lifetime, and a significant proportion of those with psychotic illness present acutely, either in relapse or with medication-related complications. Beyond psychiatric indications, antipsychotics such as prochlorperazine and domperidone are used as antiemetics, and haloperidol and droperidol are used for procedural sedation and acute behavioural disturbance. The MRCEM Primary syllabus requires candidates to understand antipsychotic pharmacology across all these contexts. NICE guidance on psychosis and schizophrenia provides the clinical framework within which these drugs are prescribed, and ED clinicians must be comfortable recognising and managing the full spectrum of antipsychotic-related presentations.

Classification and Receptor Pharmacology

Antipsychotics are divided into first-generation (typical) and second-generation (atypical) agents based on their receptor-binding profiles and the era of their development. This classification is pharmacologically meaningful rather than merely historical.

First-Generation (Typical) Antipsychotics

Agents in this class include haloperidol, chlorpromazine, prochlorperazine, and flupentixol. Their defining characteristic is high-affinity D2 receptor blockade with relatively limited serotonergic activity. Haloperidol is a high-potency agent: potent D2 blockade produces reliable antipsychotic efficacy but a high burden of extrapyramidal side effects and relatively little sedation. Chlorpromazine, by contrast, is a low-potency agent with substantial H1 (histamine) and alpha-1 adrenoceptor blockade, resulting in pronounced sedation and postural hypotension but a comparatively lower EPS burden than haloperidol. This potency distinction is clinically testable and appears regularly in MRCEM SBA question stems.

Second-Generation (Atypical) Antipsychotics

Agents in this class include olanzapine, risperidone, quetiapine, clozapine, aripiprazole, and amisulpride. The distinguishing pharmacological feature of most second-generation agents is concurrent high-affinity 5-HT2A receptor blockade alongside D2 blockade. Serotonergic blockade in the nigrostriatal pathway appears to attenuate the EPS burden associated with D2 blockade, explaining the lower extrapyramidal side effect profile of this class. Metabolic effects, including weight gain, hyperglycaemia, and dyslipidaemia, are more prominent with second-generation agents, particularly olanzapine and clozapine, owing in part to H1 and 5-HT2A blockade.

Receptor Blockade and Resultant Clinical Effects

Understanding antipsychotic pharmacology through a receptor-by-receptor lens is the most efficient approach for MRCEM Primary pharmacology revision. The following relationships are high-yield:

• D2 blockade, mesolimbic pathway: Reduction of positive psychotic symptoms (hallucinations, delusions, thought disorder). This is the therapeutic effect.
• D2 blockade, nigrostriatal pathway: Disruption of the dopamine-acetylcholine balance producing a relative cholinergic excess, which manifests as extrapyramidal side effects.
• D2 blockade, tuberoinfundibular pathway: Elevation of prolactin secretion, causing galactorrhoea, amenorrhoea, and gynaecomastia.
• D2 blockade, mesocortical pathway: Potential worsening of negative symptoms of schizophrenia (blunted affect, poverty of speech, social withdrawal).
• H1 blockade: Sedation and weight gain.
• Alpha-1 adrenoceptor blockade: Postural hypotension and reflex tachycardia. This is particularly important in elderly patients and in overdose.
• Muscarinic (M1) blockade: Dry mouth, urinary retention, constipation, blurred vision, and tachycardia. Anticholinergic effects partially offset EPS by rebalancing the dopamine-acetylcholine ratio.
• 5-HT2A blockade: Reduced EPS relative to typical agents; contributes to antipsychotic efficacy and to weight gain.
• hERG potassium channel blockade (indirect): QTc prolongation and risk of torsade de pointes. Most clinically significant with intravenous haloperidol, droperidol, and amisulpride.

Adverse Effects and Toxicological Presentations in the ED

Extrapyramidal Side Effects: Time Course and Management

The time course of EPS is a repeated exam focus. A useful mnemonic is ADAPT: Acute dystonia (hours to days), Drug-induced parkinsonism (days to weeks), Akathisia (days to weeks), Pseudo (bridging to tardive), Tardive dyskinesia (months to years). Each has a distinct clinical presentation and management approach.

Acute dystonia presents with sustained involuntary muscle contractions: oculogyric crisis, torticollis, trismus, or opisthotonus. It is caused by relative cholinergic excess in the nigrostriatal pathway following D2 blockade. Emergency treatment is procyclidine 5 mg intravenously or intramuscularly, or benzatropine 1 to 2 mg IM or IV per the British National Formulary. Response is typically rapid and diagnostically reassuring.

Akathisia is a subjective sense of inner motor restlessness with a compulsion to move. It is easily mistaken for agitation or worsening psychosis, and misidentification can lead to inappropriate dose escalation of the offending drug. Management options include propranolol, benzodiazepines, or dose reduction.

Tardive dyskinesia manifests as involuntary, repetitive oro-facial movements (lip-smacking, tongue protrusion, chewing) and choreiform limb movements following prolonged exposure. It may be irreversible and is associated with long-term high-potency typical antipsychotic use.

Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome is an idiosyncratic, potentially fatal reaction to antipsychotic drugs (and occasionally other dopamine-depleting agents). The cardinal features are hyperthermia, lead-pipe muscular rigidity, autonomic instability (labile blood pressure, tachycardia, diaphoresis), and altered consciousness. Creatine kinase is markedly elevated, reflecting rhabdomyolysis, and leukocytosis is common. NMS must be distinguished from serotonin syndrome: NMS has a slower onset (days), predominant rigidity rather than clonus or hyperreflexia, and a history of antipsychotic initiation or dose change rather than serotonergic drug use.

ED management is primarily supportive: cessation of the offending agent, active cooling, aggressive intravenous fluid resuscitation to protect renal function from myoglobulinuria, and monitoring for acute kidney injury. In severe cases, dantrolene (which reduces skeletal muscle calcium release) and bromocriptine (a D2 agonist that partially reverses central dopamine blockade) may be used, though evidence for their efficacy comes from case series rather than randomised trials. Benzodiazepines are useful for muscle relaxation and autonomic control. The Royal College of Emergency Medicine RCEM curriculum identifies NMS as a core clinical condition requiring competent ED management.

QTc Prolongation and Torsade de Pointes

Antipsychotics, particularly haloperidol given intravenously, droperidol, and amisulpride, block cardiac hERG potassium channels, prolonging phase 3 repolarisation and the QT interval. A QTc exceeding 500 ms or an increase of more than 60 ms from baseline is considered a threshold for significant torsade de pointes risk. In the ED setting, ECG monitoring is mandatory when parenteral antipsychotics are administered at higher doses, and serum electrolytes (especially potassium and magnesium) should be optimised. Overdose with any antipsychotic warrants a 12-lead ECG and continuous monitoring.

Clozapine-Specific Risks

Clozapine is reserved for schizophrenia that has failed adequate trials of at least two other antipsychotics. Its unique receptor profile includes high affinity for D4, 5-HT2, H1, muscarinic, and alpha adrenoceptors with relatively lower D2 affinity. Its superior efficacy in treatment-resistant schizophrenia comes at significant cost: agranulocytosis occurs in approximately 1 to 2 percent of patients and can be fatal. Mandatory haematological monitoring under the UK Clozapine Patient Monitoring Service is a legal and clinical requirement, referenced in NICE guidance on schizophrenia. In the ED, any clozapine-treated patient presenting with infection or neutropenia must have an urgent full blood count. Clozapine also lowers the seizure threshold more than most other antipsychotics and carries a dose-dependent risk.

How the MRCEM Primary Tests Antipsychotic Pharmacology

The MRCEM Primary examination uses the single best answer (SBA) format to test mechanistic pharmacological understanding. Antipsychotic questions typically present clinical vignettes requiring candidates to identify the receptor basis of a particular adverse effect, select the appropriate ED treatment, or distinguish between drug classes. Common question stems include: a patient developing oculogyric crisis after prochlorperazine (testing EPS mechanism and treatment); a patient with hyperprolactinaemia on antipsychotics (testing tuberoinfundibular pathway); a patient presenting with hyperthermia and rigidity after a depot antipsychotic was commenced (testing NMS recognition); or an overdose scenario requiring ECG interpretation and identification of QTc risk.

The MRCEM Primary syllabus maps to the RCEM curriculum domains of pharmacology and toxicology. Candidates who revise antipsychotics by receptor mechanism rather than by drug name will perform more reliably across the breadth of stems the exam can generate. The exam rarely asks for doses from memory in the Primary, but it does test whether you can reason from first principles about mechanism and consequence.

Revision Pearls: High-Yield Facts for MRCEM Primary Pharmacology Revision

1. The four dopamine pathways are mesolimbic, nigrostriatal, tuberoinfundibular, and mesocortical. D2 blockade in each produces, respectively: antipsychotic effect, EPS, hyperprolactinaemia, and potential worsening of negative symptoms.
2. Haloperidol is high-potency with a high EPS burden and low sedation; chlorpromazine is low-potency with prominent H1 and alpha-1 blockade producing sedation and postural hypotension.
3. Second-generation antipsychotics have lower EPS risk because concurrent 5-HT2A blockade in the nigrostriatal pathway attenuates the effect of D2 blockade.
4. The ADAPT mnemonic captures the EPS time course: Acute dystonia (hours to days), Drug-induced parkinsonism (days to weeks), Akathisia (days to weeks), Pseudo-transition, Tardive dyskinesia (months to years).
5. Acute dystonia is treated with procyclidine 5 mg IV or IM. The mechanism of benefit is anticholinergic activity restoring the dopamine-acetylcholine balance in the nigrostriatal pathway.
6. NMS is distinguished from serotonin syndrome by slower onset, lead-pipe rigidity (rather than clonus), markedly elevated CK, and association with antipsychotic use rather than serotonergic drugs.
7. Clozapine requires mandatory haematological monitoring. Any clozapine patient with infection or leucopenia presenting to the ED must have an urgent FBC and the monitoring service notified.
8. QTc prolongation risk is highest with intravenous haloperidol, droperidol, and amisulpride. Optimise potassium and magnesium before administering these agents, and obtain a baseline ECG.

Common Pitfalls: Where Candidates Lose Marks

• Confusing NMS with serotonin syndrome in a vignette. The tempo of onset, the nature of the motor signs (rigidity versus clonus and hyperreflexia), and the drug history are the discriminating features.
• Assuming all second-generation antipsychotics are safe in terms of EPS. Risperidone, particularly at higher doses, has a significant D2 affinity and EPS burden approaching that of some typical agents.
• Overlooking that akathisia may present as agitation and lead to inappropriate escalation of the antipsychotic dose, worsening the problem.
• Forgetting that muscarinic blockade by some antipsychotics (chlorpromazine, olanzapine, clozapine) produces anticholinergic toxidrome features in overdose: mydriasis, tachycardia, urinary retention, dry skin, and confusion.
• Missing QTc prolongation in overdose because an ECG was not obtained or the QT interval was not corrected for heart rate. Use Bazett or Fridericia formulae, or use an ECG machine correction.
• Attributing galactorrhoea or amenorrhoea in a patient on antipsychotics to a new prolactinoma without first considering the tuberoinfundibular D2 blockade effect.

How EM Learning Centre Supports Your MRCEM Primary Revision

Pharmacology topics of this depth and clinical relevance form a core pillar of the MRCEM Primary revision course at EM Learning Centre. Our structured lessons take a mechanism-first approach to antipsychotics, anticoagulants, analgesics, and the full breadth of the MRCEM Primary pharmacology revision syllabus, with integrated SBA practice questions mapped directly to the RCEM curriculum. Every question in our bank includes a detailed explanation of why the correct answer is correct and, crucially, why the distractors are wrong, which is where exam performance is often determined. Whether you are beginning your revision cycle or fine-tuning in the final weeks before your exam, the EM Learning Centre homepage provides a clear pathway through the Primary syllabus. Our platform is designed by UK Emergency Medicine clinicians who understand how the exam is constructed, what the examiners are testing, and how to present pharmacological concepts in a way that sticks under exam pressure.

References

1. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. NICE guideline CG178. NICE (nice.org.uk).
2. British National Formulary. Antipsychotic drugs: prescribing guidance. British National Formulary (bnf.nice.org.uk).
3. Royal College of Emergency Medicine. RCEM Curriculum 2021. Royal College of Emergency Medicine (rcem.ac.uk).
4. Resuscitation Council UK. Advanced Life Support guidelines: management of tachyarrhythmias. Resuscitation Council UK (resus.org.uk).
5. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. The BMJ (bmj.com).